Philippe Erbs

This inventor holds 17 USPTO granted patents and 4 published patent applications, plus 7 CIPO patents and 7 EPO patents. Top assignee: Transgene S.a.. Active years: 2003-2018.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Philippe Erbs. Retrieved from https://idiyas.com/inventor/philippe-erbs

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 17 (Patent Applications = 4)

% Patents Active = 35.3

CIPO Patents = 7 (Patent Applications = 2)

EPO Patents = 7 (Patent Applications = 7)

Average Co-Inventor Count = 1.8

ph-index = 4

Forward Citations = 61(Granted Patents)

Location History:

Strasbourg, FR (2003 - 2015)
Molsheim, FR (2017)
Dagneux, FR (2013 - 2018)

Company Filing History:

17 out of 159

Transgene S.a.

patents

Years Active: 2003-2018

Loading Chart...

17 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 9884080 - Poxviral oncolytic vectors (2018-02-06),

2. 9687515 - Poxviral oncolytic vectors (2017-06-27),

3. 9180150 - Poxviral oncolytic vectors (2015-11-10),

4. 9024003 - Avian telomerase reverse transcriptase (2015-05-05),

5. 8778328 - Poxviral oncolytic vectors (2014-07-15),

6. 8513018 - Immortalized avian cell lines (2013-08-20),

7. 8470591 - Kit of parts designed for implementing an antitumoral or antiviral treatment in a mammal (2013-06-25),

8. 8361788 - Immortalized avian cell lines comprising E1A nucleic acid sequences (2013-01-29),

9. 8357531 - Immortalized avian cell lines (2013-01-22),

10. 8257692 - Polypeptide having an improved cytosine deaminase activity (2012-09-04),

11. 8226954 - Polypeptide having an improved cytosine deaminase activity (2012-07-24),

12. 8211421 - Mutant having uracil phosphoribosyl transferase activity (2012-07-03),

13. 7790445 - Polypeptide having an improved cytosine deaminase activity (2010-09-07),

14. 7572438 - Mutant having uracil phosphoribosyl transferase activity (2009-08-11),

15. 7348014 - Poxvirus with targeted infection specificity (2008-03-25),

Title: Innovations by Philippe Erbs: Pioneering Cancer Treatments

Introduction

Philippe Erbs, a distinguished inventor based in Strasbourg, France, has made significant contributions to the field of cancer treatment through his innovative work. With a remarkable portfolio of 17 patents, he has focused his efforts on developing novel therapeutic methods that leverage poxviral oncolytic vectors.

Latest Patents

Among his latest patents, Philippe has developed an innovative poxvirus comprising a defective F4L and/or I4L gene. This invention relates to compositions that include such a poxvirus and outlines the methods and uses of these compositions for therapeutic purposes, specifically targeting cancer treatment. His work in this area showcases his commitment to advancing medical technology and improving patient outcomes.

Career Highlights

Philippe Erbs is actively associated with Transgene S.A., a company that specializes in the development of innovative immunotherapies for the treatment of cancer. His work at this leading research institution has positioned him at the forefront of cancer research and biotechnology, allowing him to translate his inventions into practical applications.

Collaborations

Philippe collaborates with notable coworkers in the field, including Richard Jund and Johann Foloppe. Their combined expertise fosters a dynamic environment for innovation, enabling groundbreaking research that has the potential to change the landscape of cancer therapies.

Conclusion

In summary, Philippe Erbs is a prominent inventor whose contributions to the field of cancer treatment through his patents and collaborative efforts are noteworthy. His innovative approaches and dedication to medical research are vital for the future of therapeutic options available for patients battling cancer.

Profile summary based on public USPTO records.